Effects of Vitamin D and Calcium on Hyperglycemia and Dyslipidemia in Patients Gestational Diabetes
Key facts
- Who runs it
- Riphah International University
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 28 Jan 2025
- Ended
- 5 Mar 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- vitamin D3
- Record updated
- 17 March 2026
Who can take part
- Age
- 18 years to 40 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Pregnant women aged 18-40 years
- Gestational age between 24-28 weeks
- Diagnosis of GDM based on OGTT results
- Willingness of participants to provide written informed consent
Who cannot take part
- Pre-existing diabetes mellitus (type 1 or type 2)
- Chronic kidney or liver disease
- Use of vitamin D or calcium supplements in the last 3 months
- Multiple pregnancies (twins, triplets)
- Any major pregnancy complications (e.g., preeclampsia)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Gestational diabetes mellitus (GDM) is becoming more common globally as a metabolic disease that occurs during pregnancy and influences the mother and the fetus. It has been linked to preeclampsia, C-section, and a higher lifetime risk of developing type 2 diabetes both for mother and the child. Another complication of GDM is dyslipidemia that also accentuates cardiovascular risks, so the care of lipid profiles is essential for the best pregnancy outcomes. The previous literature review indicates that micronutrients including vitamin D and calcium have a bearing on glucose and lipid profiles. Various studies have established that vitamin D improves the insulin response and lipid profile whereas calcium is vital in insulin and glucose homeostasis. Furthermore, it is revealed that calcium induces vitamin D so that it could undergo its full metabolic effect. Hence, the addition of vitamin D and calcium together may enhance glycemic management and lipid profiles of GDM patients. The aim of the present work is to compare the impact of vitamin D and calcium supplementation on lipid profiles and hyperglycemia in GDM patients. It will measure the major metabolic indices fasting plasma glucose, glycated hemoglobin (HbA1c) and lipid profile (LDL, HDL triglycerides) and review the effect of this on pregnancy outcomes. These outcomes will be assessed by a randomized-controlled trial.
The 2 groups in the trial
- Arm and InterventionsOther group
Experimental: Vitamin D3 and calcium This group will be receive vitamin D3 600 IU and 1.5 g of calcium. This treatment will be conducted for 6 week per day after meal.
Treatment: vitamin D3
- Arm and placeboOther group
: This group will receive a placebo containing no active ingredients and it will conducted for 6 weeks per day.
Treatment: vitamin D3
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Synergistic Effects of Vitamin D and Calcium Supplementation on Hyperglycemia and Dyslipidemia in Patients With Gestational Diabetes
- Record updated
- 17 March 2026